Roy S Roberts Net Worth

The estimated Net Worth of Roy S Roberts is at least $5.45 Миллион dollars as of 20 October 2009. Roy Roberts owns over 6,413 units of Abbvie Inc stock worth over $5,454,941 and over the last 21 years Roy sold ABBV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Roy Roberts ABBV stock SEC Form 4 insiders trading

Roy has made over 2 trades of the Abbvie Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Roy exercised 6,413 units of ABBV stock worth $239,974 on 20 October 2009.

The largest trade Roy's ever made was exercising 9,427 units of Abbvie Inc stock on 8 February 2008 worth over $329,945. On average, Roy trades about 990 units every 39 days since 2004. As of 20 October 2009 Roy still owns at least 28,033 units of Abbvie Inc stock.

You can see the complete history of Roy Roberts stock trades at the bottom of the page.

What's Roy Roberts's mailing address?

Roy's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell и Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.

What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Complete history of Roy Roberts stock trades at Abbott Laboratories и Abbvie Inc

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include:

• Richard Gonzalez,
  Chairman of the Board, Chief Executive Officer
• Laura Schumacher,
  Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban,
  Vice Chairman, Chief Commercial Officer
• Michael Severino,
  President, Vice Chairman
• Robert Michael,
  Chief Financial Officer, Senior Vice President
• William Chase,
  Executive Vice President - Finance and Administration
• Richard A. Gonzalez,
  Chairman & CEO
• Dr. Michael E. Severino,
  Vice Chairman & Pres
• Laura J. Schumacher,
  Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
• Timothy Richmond,
  Chief Human Resource Officer, Executive Vice President
• Robert A. Michael,
  Vice Chairman of Fin. & Commercial Operations and CFO
• Glenn Tilton,
  Lead Independent Director
• Robert Alpern,
  Independent Director
• Edward Rapp,
  Independent Director
• Brett Hart,
  Independent Director
• William Burnside,
  Independent Director
• Roxanne Austin,
  Independent Director
• Frederick Waddell,
  Independent Director
• Melody Meyer,
  Independent Director
• Edward Liddy,
  Independent Director
• Thomas Freyman,
  Independent Director
• Rebecca Roberts,
  Independent Director
• Brian Durkin,
  Vice President, Controller
• Jeffrey Stewart,
  Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe,
  Senior Vice President - Enterprise Innovation
• Azita Saleki-Gerhardt,
  Executive Vice President - Operations
• Henry Gosebruch,
  Executive Vice President, Chief Strategy Officer
• Scott T. Reents,
  Sr. VP & CFO
• Jeffrey Ryan Stewart,
  Exec. VP & Chief Commercial Officer
• Henry O. Gosebruch,
  Exec. VP & Chief Strategy Officer
• Scott C. Brun M.D.,
  VP of Scientific Affairs & Head of AbbVie Ventures
• Timothy J. Richmond,
  Exec. VP & Chief HR Officer
• Elizabeth Shea,
  VP of Investor Relations
• Dr. Thomas J. Hudson,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Azita Saleki-Gerhardt,
  Exec. VP of Operations
• Thomas A. Hurwich,
  VP, Controller
• Jennifer L. Davis,
  
• Roy S Roberts,
  Director
• Laboratories Abbott,
  10% owner
• John M Leonard,
  SVP, Chief Scientific Officer
• Elaine K. Sorg,
  SVP, US COMMERCIAL OPERATIONS
• Perry C Siatis,
  EVP, GC AND SECRETARY
• Carrie C Strom,
  SVP & PRES GLOBAL ALLERG AESTH
• Thomas J Hudson,
  SVP, CSO, GLOBAL RESEARCH
• Scott T Reents,
  EVP, CHIEF FINANCIAL OFFICER
• Susan E Quaggin,
  
• Kevin K Buckbee,
  SVP, CONTROLLER
• Roopal Thakkar,
  SVP, CMO, GLOBAL THERAPEUTICS